{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:56:56Z","timestamp":1786985816658,"version":"build-2736575974"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cca.2026.121116","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:33:21Z","timestamp":1779464001000},"page":"121116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["JAK2 V617F as a diagnostic and prognostic biomarker in myeloproliferative neoplasms"],"prefix":"10.1016","volume":"590","author":[{"given":"Asif Ahmad","family":"Bhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivkanya","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Narain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmashini","family":"Gnanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish Vasanth","family":"Dhandapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangita","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj Kumar","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121116_bb0005","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.clml.2011.04.002","article-title":"BCR-ABL1\u2013negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment","volume":"11","author":"Vakil","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.cca.2026.121116_bb0010","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.cca.2026.121116_bb0015","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood.2023019876","article-title":"Introduction to a review series on classic myeloproliferative neoplasms","volume":"141","author":"Cazzola","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0020","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia Vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"2023","key":"10.1016\/j.cca.2026.121116_bb0025","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0030","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121116_bb0035","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1038\/s41375-024-02425-1","article-title":"Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase","volume":"38","author":"Walter","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121116_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-025-01235-7","article-title":"Evolution of WHO diagnostic criteria in \"classical myeloproliferative neoplasms\" compared with the international consensus classification","volume":"15","author":"Thiele","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2026.121116_bb0045","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cca.2026.121116_bb0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cca.2026.121116_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ph15020160","article-title":"JAK2 in myeloproliferative neoplasms: still a protagonist","volume":"15","author":"Bader","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.cca.2026.121116_bb0060","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1091\/mbc.e02-06-0342","article-title":"Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its Pseudokinase domain","volume":"14","author":"Saharinen","year":"2002","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cca.2026.121116_bb0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.cca.2026.121116_bb0070","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/2159-8290.CD-22-0952","article-title":"Jak2V617F reversible activation shows its essential requirement in myeloproliferative neoplasms","volume":"14","author":"Dunbar","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cca.2026.121116_bb0075","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cca.2026.121116_bb0085","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0090","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2012.079129","article-title":"Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia","volume":"98","author":"Godfrey","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121116_bb0095","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121116_bb0100","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121116_bb0105","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2026.121116_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00428-022-03480-8","article-title":"International consensus classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms","volume":"482","author":"Gianelli","year":"2023","journal-title":"Virchows Arch."},{"key":"10.1016\/j.cca.2026.121116_bb0120","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clml.2024.08.005","article-title":"SOHO state of the art updates and next questions | approach to BCR::ABL1-like acute lymphoblastic Leukemia","volume":"25","author":"Iacobucci","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.cca.2026.121116_bb0130","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with Essential Thrombocythemia and Polycythemia Vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.20721","article-title":"Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera","volume":"82","author":"Ganly","year":"2007","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0140","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/10428190701885537","article-title":"JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera","volume":"49","author":"Zhang","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.cca.2026.121116_bb0145","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","article-title":"JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis","volume":"37","author":"Hussein","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0150","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5045\/br.2013.48.2.128","article-title":"The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasm","volume":"48","author":"Park","year":"2013","journal-title":"Blood Res."},{"key":"10.1016\/j.cca.2026.121116_bb0155","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2026.121116_bb0160","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1007\/s00277-024-05896-5","article-title":"Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR","volume":"103","author":"Lu","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0165","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00277-025-06326-w","article-title":"Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2(V617F) variant allelic fraction in a real-world cohort","volume":"104","author":"Lebecque","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0170","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.humpath.2006.05.006","volume":"37","author":"Bousquet","year":"2006","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.cca.2026.121116_bb0175","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/sj.leu.2404588","article-title":"Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2V617F","volume":"21","author":"Hermouet","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121116_bb0180","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2353\/jmoldx.2006.050130","article-title":"Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis","volume":"8","author":"Lay","year":"2006","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121116_bb0185","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1309\/AJCPFHUQZ9AGUEKA","article-title":"Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods","volume":"132","author":"Cankovic","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.cca.2026.121116_bb0190","doi-asserted-by":"crossref","first-page":"37239","DOI":"10.18632\/oncotarget.16744","article-title":"The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study","volume":"8","author":"Perricone","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2026.121116_bb0195","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00277-018-3570-8","article-title":"International external quality assurance of JAK2 V617F quantification","volume":"98","author":"Asp","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0200","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/hon.800","article-title":"A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood","volume":"24","author":"Poodt","year":"2006","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.cca.2026.121116_bb0205","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2353\/jmoldx.2010.090137","article-title":"A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide","volume":"12","author":"Denys","year":"2010","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121116_bb0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12075","article-title":"Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations","volume":"160","author":"Bench","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cca.2026.121116_bb0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cca.2009.07.002","article-title":"Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation","volume":"408","author":"Er","year":"2009","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.121116_bb0220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.plabm.2015.12.004","article-title":"Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms","volume":"4","author":"Didone","year":"2016","journal-title":"Pract. Lab. Med."},{"key":"10.1016\/j.cca.2026.121116_bb0225","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00277-016-2623-0","article-title":"Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR","volume":"95","author":"Waterhouse","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0230","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00277-018-3451-1","article-title":"A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs","volume":"97","author":"Link-Lenczowska","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0235","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0044-1785537","article-title":"Laboratory-developed droplet digital PCR assay for quantification of the JAK2 (V617F) mutation","volume":"11","author":"Liu","year":"2024","journal-title":"Glob. Med. Genet."},{"key":"10.1016\/j.cca.2026.121116_bb0240","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jmoldx.2016.05.006","article-title":"Rapid molecular profiling of myeloproliferative neoplasms using targeted exon resequencing of 86 genes involved in JAK-STAT Signaling and epigenetic regulation","volume":"18","author":"Magor","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121116_bb0245","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/bjh.17087","article-title":"Circulating cell-free DNA improves the molecular characterisation of Ph-negative myeloproliferative neoplasms","volume":"192","author":"Garcia-Gisbert","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cca.2026.121116_bb0250","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2353\/jmoldx.2007.060125","article-title":"Quantitative determination of JAK2 V617F by TaqMan: an absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders","volume":"9","author":"Hammond","year":"2007","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121116_bb0255","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.13486","article-title":"Concordance of assays designed for the quantification of JAK2V617F: a multicenter study","volume":"94","author":"Lippert","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121116_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026534","article-title":"Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera","volume":"6","author":"Wu","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.cca.2026.121116_bb0265","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/gtmb.2012.0366","article-title":"Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples","volume":"17","author":"Collier","year":"2013","journal-title":"Genet. Test. Mol. Biomarkers."},{"key":"10.1016\/j.cca.2026.121116_bb0270","doi-asserted-by":"crossref","first-page":"32608","DOI":"10.18632\/oncotarget.15940","article-title":"Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories","volume":"8","author":"Perricone","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2026.121116_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.70180","article-title":"Validation of the Primerdesign quantitative allele specific amplification kit for the detection of JAK2V617F mutation","author":"Vaz","year":"2026","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.cca.2026.121116_bb0280","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","article-title":"The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis\u2013impact on disease phenotype","volume":"79","author":"Larsen","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.cca.2026.121116_bb0285","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121116_bb0290","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0295","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12185-013-1475-9","article-title":"JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients","volume":"99","author":"Coucelo","year":"2014","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0300","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5045\/br.2021.2021089","article-title":"Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden","volume":"56","author":"Lee","year":"2021","journal-title":"Blood Res."},{"key":"10.1016\/j.cca.2026.121116_bb0305","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1007\/s11845-024-03776-5","article-title":"Association between JAK2(V617F) variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms","volume":"193","author":"Brown","year":"2024","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.cca.2026.121116_bb0310","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in Idiopathic Myelofibrosis","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0315","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"M.P.D.R.C. For the, prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121116_bb0320","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in Primary Myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0325","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121116_bb0330","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0335","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41408-020-00364-5","article-title":"ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden","volume":"10","author":"Wang","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2026.121116_bb0340","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2008.001271","article-title":"Clinical relevance of JAK2 (V617F) mutant allele burden","volume":"94","author":"Passamonti","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121116_bb0345","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3324\/haematol.13721","article-title":"JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis","volume":"94","author":"Guglielmelli","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121116_bb0350","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00277-024-05754-4","article-title":"Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis","volume":"103","author":"Chen","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0355","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0360","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121116_bb0365","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121116_bb0370","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0375","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0380","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1309\/AJCP3Z2AKUWRGTNM","article-title":"Bone marrow morphologic features in Polycythemia Vera with JAK2 exon 12 mutations","volume":"133","author":"Lakey","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.cca.2026.121116_bb0385","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121116_bb0390","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121116_bb0395","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3324\/haematol.12011","article-title":"JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis","volume":"92","author":"Mart\u00ednez-Avil\u00e9s","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121116_bb0400","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3324\/haematol.13223","article-title":"Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera","volume":"94","author":"Schnittger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121116_bb0405","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3343\/alm.2015.35.6.651","article-title":"Straightforward identification of masked polycythemia vera based on proposed revision of World Health Organization diagnostic criteria for BCR-ABL1-negative myeloproliferative neoplasms","volume":"35","author":"Chu","year":"2015","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.cca.2026.121116_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2019.102355","article-title":"The role of a low erythropoietin level for the polycythemia vera diagnosis","volume":"80","author":"Lupak","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.cca.2026.121116_bb0415","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1007\/s11606-022-07963-x","article-title":"A rational approach to JAK2 mutation testing in patients with elevated Hemoglobin: results from the JAK2 prediction cohort (JAKPOT) study","volume":"38","author":"Chin-Yee","year":"2023","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.cca.2026.121116_bb0420","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3390\/diagnostics14171902","article-title":"Diagnostic performance of serum erythropoietin to discriminate Polycythemia Vera from secondary erythrocytosis through established subnormal limits","volume":"14","author":"Yoon","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.cca.2026.121116_bb0425","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.23676","article-title":"JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events","volume":"89","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0430","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121116_bb0435","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2010.06.017","article-title":"JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy","volume":"35","author":"Silver","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cca.2026.121116_bb0440","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cca.2026.121116_bb0445","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for Polycythemia Vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.121116_bb0450","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3324\/haematol.2011.053348","article-title":"Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera","volume":"97","author":"Kuriakose","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121116_bb0455","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmoldx.2013.07.002","article-title":"Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: A report of the Association for Molecular Pathology","volume":"15","author":"Gong","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121116_bb0460","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/jclinpath-2018-205527","article-title":"JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing","volume":"72","author":"Mahe","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.cca.2026.121116_bb0465","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11845-019-02100-w","article-title":"A molecular diagnostic algorithm for JAK2 V617F investigations in suspected myeloproliferative neoplasms","volume":"189","author":"Catherwood","year":"2020","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.cca.2026.121116_bb0470","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jmoldx.2024.10.003","article-title":"Analysis of molecular testing for suspected myeloproliferative neoplasm at a hybrid community-academic health system","volume":"27","author":"Stone","year":"2025","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121116_bb0475","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121116_bb0480","doi-asserted-by":"crossref","DOI":"10.1097\/PAI.0000000000000228","article-title":"Is low positive JAK2 V617F mutation test result clinically significant?: multi-institutional study","volume":"24","author":"Wu","year":"2016","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.cca.2026.121116_bb0485","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3390\/diagnostics13122086","article-title":"A comparison of bone marrow morphology and peripheral blood findings in low and high level JAK2 V617F allele burden","volume":"13","author":"Babarovi\u0107","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.cca.2026.121116_bb0490","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037751","article-title":"JAKCalc: A machine-learning approach to rationalized JAK2 testing in patients with elevated hemoglobin levels","volume":"103","author":"Koseoglu","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cca.2026.121116_bb0495","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16183149","article-title":"Real-world impact of deep targeted sequencing on erythrocytosis and thrombocytosis diagnosis: a reference centre experience","volume":"16","author":"Blanco-S\u00e1nchez","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2026.121116_bb0500","first-page":"2691","article-title":"Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms","volume":"110","author":"Yu","year":"2025","journal-title":"Haematologica"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126002986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126002986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:29:01Z","timestamp":1783643341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126002986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":100,"alternative-id":["S0009898126002986"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121116","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK2 V617F as a diagnostic and prognostic biomarker in myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121116"}}